Previous close | 17.96 |
Open | 18.20 |
Bid | 20.60 x 500 |
Ask | 20.65 x 500 |
Day's range | 18.13 - 20.75 |
52-week range | 16.92 - 41.06 |
Volume | |
Avg. volume | 1,771,216 |
Market cap | 2.511B |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PALO ALTO, Calif., March 13, 2024--ECLIPSE study to be published in NEJM shows Shield blood-based screening test detects 83% of people with colorectal cancer.
PALO ALTO, Calif., March 06, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 29,048 shares of its common stock to one new non-executive employee with a grant da
PALO ALTO, Calif., March 01, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.